The impact of side effects on long-term retention in three new antiepileptic drugs

Seizure

Volumn 18, Issue 5, 2009, Pages 327-331

  Bootsma, Hans P ^a   Ricker, Lukas ^a   Hekster, Yechiel A ^c   Hulsman, Jacques ^a   Lambrechts, Danielle ^a   Majoie, Marian ^a   Schellekens, Ad ^a   de Krom, Marc ^b   Aldenkamp, Albert P ^a,b  

^a Neuropsychology and Pharmacology   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antiepileptics; Cognitive function; Lamotrigine; Levetiracetam; Long term retention; Side effects of AEDs; Topiramate

Indexed keywords

ETIRACETAM; LAMOTRIGINE; TOPIRAMATE;

ADULT; ANOREXIA; ARTICLE; COGNITION; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RETENTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHASIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; PARESTHESIA; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; WEIGHT REDUCTION;

ANTICONVULSANTS; DRUG UTILIZATION; EPILEPSY; FRUCTOSE; HUMANS; LONGITUDINAL STUDIES; PATIENT COMPLIANCE; PIRACETAM; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 67349251214     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2008.11.006     Document Type: Article

References (24)

1. Sander J.W. The use of anti-epileptic drugs-principles and practice. Epilepsia 45 Suppl. 6 (2004) 28-34
2. Luciano A.L., and Shorvon S.D. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 62 (2007) 375-381
3. Callaghan B.C. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 62 (2007) 382-389
4. Otoul C., Arrigo C., Van Rijckevorsel K., and French J.A. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28 (2005) 72-78
5. Mohanraj R., and Brodie M.J. Measuring the efficacy of antiepileptic drugs. Seizure 12 (2003) 413-443
6. Lhatoo S.D., Wong I.C., Polizzi G., and Sander J.W. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41 (2000) 1592-1596
7. Knoester P.D., Keyser A., Renier W.O., Egberts A.C.G., Hekster Y.A., and Deckers C.L.P. Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study. Epilepsy Res 65 (2005) 93-100
8. Chung S., Wang N., and Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 16 (2007) 296-304
9. Ketter T.A., Post R.M., and Theodore W.H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53 Suppl. 2 (1999) S53-S67
10. Roberts G.M.P., Majoie H.J.M., Leenen L.A.M., Bootsma H.P., Kessels A.G.H., Aldenkamp A.P., et al. Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam. Epilepsy Behav 6 (2005) 366-372
11. Kaplan E.L. Non-parametric estimation from incomplete observations. Am Stat Assoc J 53 (1958) 457-481
12. Privitera M. Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry. Epilepsy Res 68 (2006) 52-56
13. Simister R.J., Sander J.W., and Koepp M.J. Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy Behav 10 (2007) 336-339
14. Chadwick D.W. Report of the ILAE commission on antiepileptic drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 39 (1988) 799-803
15. Tatum W.O., French J.A., Faught E., Morris G.L., Liporace J., Kanner A., et al. Postmarketing experience with topiramate and cognition. Epilepsia 42 (2001) 1134-1140
16. Weintraub D., Buchsbaum R., Resor Jr. S.R., and Hirsch L.J. Psychiatric and behavioural side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 10 (2007) 105-110
17. White J.R., Walczak T.S., Leppik I.E., Rarick J., Tran T., Beniak T.E., et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 61 (2003) 1218-1221
18. Blum D., Meador K., Biton V., Fakhoury T., Shneker B., Chung S., et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 67 (2006) 400-406
19. Chappell B., and Crawford P. An audit of lamotrigine, levetiracetam and topiramate usage for epilepsy in a district general hospital. Seizure 14 (2005) 422-428
20. Brunbech L., and Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy. Drugs 62 (2002) 593-604
21. Aldenkamp A.P., and Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2 (2001) 85-91
22. Smith D., Baker G., Davies G., Dewey M., and Chadwick D.W. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 34 (1993) 312-322
23. Aldenkamp A.P., Baker G., Mulder O.G., Chadwick D., Cooper P., Doelman J., et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in subjects with partial-onset seizures. Epilepsia 41 (2000) 1167-1178
24. Fritz N., Glogau S., Hoffmann J., Rademacher M., Elger C.E., and Helmsteadter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 6 (2005) 373-381